Connect with us

Daily News

DBT’s THSTI recognised as global bioassay laboratory to assess COVID-19 vaccine

The Translational Health Science and Technology Institute (THSTI) has now been recognised by the Coalition for Epidemic Preparedness Innovations (CEPI) as one of the global network of laboratories for a centralised assessment of COVID-19 vaccines, the Department of Biotechnology (DBT) said on Monday.

The mandate of the bioassay laboratory at the Faridabad-based THSTI, a premier research institute under the DBT, is to provide validated assays for vaccine development at par with global standards.

The CEPI network will initially involve six laboratories, one each in Canada, Britain, Italy, the Netherlands, Bangladesh and India. Under the CEPI global network, the laboratories will use the same reagents and follow a common set of protocols to measure the immune response of multiple vaccine candidates under development and trial.

The Ind-CEPI mission for the establishment of a BSL-3 facility is a translational laboratory for platform technologies and a bioassay laboratory for development of assays to measure clinical immunogenicity. – PTI